IO-108,pembrolizumab,cemiplimab 
Immune-Onc Therapeutics,Merck,Regeneron
['io-108', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'pembro']
#aacr23: immune-onc's io-108 showed encouraging initial clinical data as single agent and in combo with pembro in difficult-to-treat cancers including mcc, crc &amp; cholangiocarcinoma with better safety profile. data from larger patient pool is awaited for further validation 
Course5i prides itself in enabling #LifeSciences organizations with insights, #analytics and #AI to drive strategic decisions. Enabling better health outcomes.